Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments.
Bristol Myers Squibb raised its outlook for the year after notching higher profit and revenue in the latest quarter, boosted by its portfolio of newer treatments.
